Complete Target Coverage Research Articles

On Complete Targets Coverage in Rechargeable IoT Networks: A Message-Passing Approach

This article studies targets coverage in an energy harvesting (EH) Internet of Things (IoT) network. Specifically, it addresses the problem of activating subsets of EH sensor nodes to monitor targets, such as valuable assets or the ingresses and egresses of a building. A key requirement, so called complete targets coverage, is that all targets must be monitored by at least one sensor node at all times. To meet this requirement, we need to derive set covers, where each set cover is comprised of one or more sensor nodes that are activated simultaneously in each time slot. To this end, we show for the first time how the belief propagation message-passing framework can be used to derive these set covers. Advantageously, our approach does not require future energy arrivals information at devices. The results show that our message-passing approach is within 90% of the optimal coverage lifetime.

Complete Targets Coverage in Energy Harvesting Internet of Things With Ambient Backscatter

This article considers deriving set covers or the set of active nodes that are responsible for monitoring all targets in an Internet of Things (IoT) network. A key distinction to prior works is that this article considers sensor nodes aided by backscatter communications, which allow them to communicate with negligible energy cost using ambient radio frequency (RF) signals. The article contains three main novelties. First, it presents a mixed integer linear program (MILP) that can be used to compute the global optimal solution. Second, it also outlines a centralized greedy scheduling (CGS) algorithm that selects nodes based on their energy and the number of covered targets. Third, it presents a distributed greedy scheduling (DGS) algorithm that selects nodes according to their energy level. The simulation results show that equipping nodes with ambient backscattering capability increases the ratio of complete targets coverage by more than 100% as compared to existing techniques.

Complete Targets Coverage in Energy-Harvesting IoT Networks With Dual Imperfect Batteries

This paper studies the complete targets coverage problem in a novel and practical context: sensor nodes operating in an Internet of Things (IoT) network that have a dual-battery system with non-ideal properties. Specifically, sensor nodes have batteries that cannot be charged and discharged simultaneously. Also, sensor nodes must fully discharge/charge a battery before it is charged/discharged again. We outline a Mixed Integer Linear Program (MILP) and use it to optimize the activation schedule of sensor nodes. Its objective is to maximize complete targets coverage lifetime. We also propose a heuristic solution named Battery Switching Aware Algorithm (BSAA) to solve large problem instances. Simulation results show the performance of BSAA achieves approximately 98% of the coverage lifetime of MILP. In addition, equipping sensor nodes with a dual battery system prolongs the coverage lifetime by up to 70.2%.

Learning Algorithms for Complete Targets Coverage in RF-Energy Harvesting Networks

A key task in Internet of Things (IoTs) networks is determining the active time of a set of devices or set covers to monitor static targets. This task, however, requires the battery level of devices. However, in practice, it is impractical to obtain an accurate battery level or channel state information from all devices, especially in large-scale networks. To this end, we present a number of approaches to construct set covers. We first propose a Two-Phase Algorithm (TPA) that requires devices to first determine their probability of being active in each time slot. This probability is then used by a Hybrid Access Point (HAP) to construct set covers. We then introduce learning approaches based on Gibbs and Thompson sampling. The Gibbs sampling based algorithm, aka GB, allows a sink/gateway to learn the best set cover to use over time. Similarly, our Thompson sampling solutions, namely TS-Random and TS-CB, construct set covers iteratively based on the probability that a device successfully monitors static targets. The numerical results show that GB performs better than TS-CB initially but has similar performance to TS-CB in the long term.

On Max-Min Complete Targets Sampling in Backscatter-Aided RF Powered IoT Networks

This letter considers a Radio Frequency (RF) powered Internet of Things (IoT) network that exploits ambient backscatter communications to maximize the minimum number of samples of targets. We propose a Maximum Backscatter Opportunity Search (MBOS) heuristic algorithm to construct set covers to ensure complete targets coverage. Our results demonstrate that the performance of MBOS is within 91% of the optimal number of samples and it is 25% higher as compared to not using backscattering.

A Complete Continuous Target Coverage Model for Emerging Applications of Wireless Sensor Network Using Termite Flies Optimization Algorithm

A Complete Continuous Target Coverage Model for Emerging Applications of Wireless Sensor Network Using Termite Flies Optimization Algorithm

Dosimetric accuracy of dual isocenter irradiation in low magnetic field resonance guided radiotherapy system for extended abdominal tumours.

Due to limited field size of Magnetic Resonance Linear Accelerators (MR-Linac), some treatments could require a dual-isocenter planning approach to achieve a complete target coverage and thus exploit the benefits of the online adaptation. This study evaluates the dosimetric accuracy of the dual-isocenter intensity modulated radiation therapy (IMRT) delivery technique for MR-Linac. Dual-isocenter multi leaf collimator (MLC) and couch accuracy tests have been performed to evaluate the delivery accuracy of the system. A mono-isocenter plan delivered in clinical practice has then been retrospectively re-planned with dual-isocenter technique. The dual-isocenter plan has been re-calculated and delivered on a 3-dimensional (3D) ArcCHECK phantom and 2-dimensional (2D) films to assess its dosimetric accuracy in terms of gamma analysis. Clinical and planning target volume (CTV and PTV respectively) coverage robustness was then investigated after the introduction of±2mm and±5mm positioning errors by shifting the couch. MLC and couch accuracy tests confirmed the system accuracy in delivering a dual-isocenter irradiation. 2D/3D gamma analysis results occurred always to be above 95% if considered a gamma criteria 1%/2 mm and 1%/1 mm respectively for the 2D and 3D analysis. The mean variations for CTV D98% and PTV V95% were 0.2% and 1.1% respectively when positioning error was introduced separately in each direction, while the maximum observed variations were 0.9% (CTV) and 3.7% (PTV). The dosimetric accuracy of dual-isocenter irradiation has been verified for MR-Linac, achieving accurate and robust treatment strategy and improving dose conformality also in presence of targets whose extension exceeds the nominal maximum field size.

Complete Target Coverage in Radio Frequency and Solar-Powered Sensor Networks

Future Internet of Things networks are likely to have radio frequency (RF) energy harvesting sensor devices and also solar-powered hybrid access points (HAPs) that help monitor one or more targets such as assets in a warehouse. In this setting, we outline three contributions that ensure devices' monitor targets at all times and upload the maximum number of samples to an HAP in order to ensure high monitoring quality. First, we outline a mixed integer linear program (MILP) and use it to optimize the transmission power of HAPs and time used by devices to harvest RF energy, monitor target(s), and data transmissions. Second, we propose two heuristic algorithms to solve large problem instances. The results show that our heuristics achieve almost 97% of the optimal result computed by the MILP.

Computationally Guided Intracerebral Drug Delivery via Chronically Implanted Microdevices

Treatments for neurologic diseases are often limited in efficacy due to poor spatial and temporal control over their delivery. Intracerebral delivery partially overcomes this by directly infusing therapeutics to the brain. Brain structures, however, are nonuniform and irregularly shaped, precluding complete target coverage by a single bolus without significant off-target effects and possible toxicity. Nearly complete coverage is crucial for effective modulation of these structures. We present a framework with computational mapping algorithms for neural drug delivery (COMMAND) to guide multi-bolus targeting of brain structures that maximizes coverage and minimizes off-target leakage. Custom-fabricated chronic neural implants leverage rational fluidic design to achieve multi-bolus delivery in rodents through a single infusion of radioactive tracer (Cu-64). The resulting spatial distributions replicate computed spatial coverage with 5% error invivo, as detected by positron emission tomography. COMMAND potentially enables accurate, efficacious targeting of discrete brain regions.

On Complete Targets Coverage in RF-Harvesting Internet of Things Networks

This letter considers radio frequency (RF) energy harvesting and targets monitoring sensor nodes that are managed by a hybrid access point (HAP). We address a novel problem called maximizing data collected for complete targets’ coverage (MDC-CTC) that involves computing a schedule comprising the time used by the HAP for charging, and the time used by the sensor nodes for monitoring targets and data upload. We model the MDC-CTC problem as a linear program (LP) and use it to determine the optimal schedule that maximizes the amount of data collected by the HAP. In addition, we also propose a heuristic to generate a subset of set covers for use by the LP in large-scale networks. Our results show that the amount of data collected by the HAP is proportional to the number of sensor nodes or the HAP’s transmission power. Finally, using our heuristic along with the formulated LP yields results that are within 75% of the optimal result.

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Background: Bruton tyrosine kinase (BTK) is a critical component of B-cell receptor signaling and a validated target for CLL. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor, which has shown promising efficacy and safety in patients with CLL, including high-risk patients. We present preliminary efficacy, safety, and pharmacodynamic results from an ongoing single-center, open-label, phase 2 study of acalabrutinib monotherapy in patients with R/R and high-risk, TN CLL.Methods: Patients with R/R or high-risk (chromosome 17p deletion [del17p] or mutation in TP53 or NOTCH1) TN CLL/small lymphocytic lymphoma (SLL) who met International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for treatment and had an Eastern Cooperative Oncology Group performance status ≤2 were eligible. Patients who had prior BTK inhibitor therapy were excluded. Patients were randomized to receive oral acalabrutinib 100 mg twice daily (BID) or 200 mg daily (QD) until progressive disease or unacceptable toxicity. The primary endpoint was investigator-assessed overall response rate (ORR) by IWCLL 2008 criteria with modification for lymphocytosis. Secondary endpoints included safety and BTK occupancy. BTK occupancy was measured with a biotin-tagged analogue probe in peripheral blood cells at drug trough time points after 3 days of dosing and after 1, 6, and 12 mo of treatment. BTK occupancy in lymph node samples was measured at drug trough time points after 3 days of dosing.Results: Forty-six patients were enrolled and treated (100 mg BID, n=22; 200 mg QD, n=24). The median age was 64 years (range, 45-83), and 35% (16/46) were TN. Approximately 39% of patients (25% of TN) had bulky lymph nodes ≥5 cm, 37% (50% of TN) had Rai stage III-IV disease at baseline, 76% (88% of TN) had unmutatedIGHV, 21% (40% of TN) had del(17p), 21% (23% of TN) had TP53 mutation, and 47% (54% of TN) had NOTCH1 mutation. As of April 13, 2018, the median time on study for all treated patients was 20 mo (range 1-39), with 89% (41/46) remaining on acalabrutinib. Two patients (9%) in the BID group and 3 patients (13%) in the QD group discontinued treatment due to an adverse event (AE; n=1), progressive disease (n=1), and other reasons (n=3). The patient who discontinued due to progressive disease (BID group) achieved partial response at 2 mo and developed Richter transformation at 6 mo.The ORR was 90% (95% CI: 76, 97) for efficacy evaluable patients (N=39), defined per protocol as patients who had ≥ 6 mo of acalabrutinib (Table). ORR was 95% (75, 100) and 84% (60, 97) for the BID and QD group, respectively. For the intent-to-treat population (N=46), ORR was 80% (66, 91). Most AEs were grade 1/2 and did not require dose delays or modifications. The most common AEs (all grades; >25%) were headache (63%), contusion (50%), diarrhea (43%), upper respiratory tract infection (43%), arthralgia (33%), influenza-like illness (28%), maculo-papular rash (28%), myalgia (26%), and nausea (26%). Grade 3/4 AEs occurred in 33% (15/46) of patients (BID, 27% [6/22]; QD, 38% [9/24]), most commonly (>10%) infections (13%; urinary tract infection, lung infection, hepatitis B reactivation, which led to treatment discontinuation and fatal hepatic failure after 10 mo of treatment, and an invasive pulmonary aspergillosis at 2 mo in the setting of prolonged neutropenia and recent systemic corticosteroid use that led to treatment discontinuation) and neutropenia (11%). Approximately 33% (15/46) of patients (BID, 23% [5/22]; QD, 42% [10/24]) reported serious AEs (all grades), most commonly (>5%) lung infection (7%). No atrial fibrillation was reported, and one grade 1 atrial flutter occurred (BID).On day 4 of cycle 1, median trough BTK occupancy was significantly higher for the BID group versus the QD group in the peripheral blood (95% vs 87%; P<0.001) and in the lymph node (98% vs 90%, P<0.001). Median trough BTK occupancy in the peripheral blood was also higher for the BID group at 1, 6, and 12 mo (range, 98%-99% for BID vs 95%-97% for QD; P<0.05 at all time points).Conclusion: Acalabrutinib monotherapy produced high ORR in R/R and high-risk TN CLL, with an acceptable safety profile. The study was not designed to detect a statistically significant difference in clinical outcomes between the dosing groups. Near complete target coverage (>95%) was more rapidly achieved with 100 mg BID than 200 mg QD dosing in the lymph node and peripheral blood. [Display omitted] DisclosuresNierman:National Institutes of Health: Employment. Covey:Acerta Pharma: Employment; AstraZeneca: Equity Ownership. Hamdy:Acerta Pharma: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: various patents for ACP-196. Izumi:Acerta Pharma: Employment, Equity Ownership, Patents & Royalties: Acerta Pharma, various patents for ACP-196. Liu:Acerta Pharma: Employment. Patel:Acerta Pharma: Employment, Equity Ownership. Wiestner:Pharmacyclics LLC, an AbbVie Company: Research Funding.

Complete Targets Coverage in Wireless Sensor Networks With Energy Transfer

This letter considers energy harvesting sensor nodes monitoring multiple fixed targets. The goal is to monitor these targets for the longest time period. A key challenge, however, is that sensor nodes have varying energy harvesting rates, meaning that the coverage lifetime of targets is limited by sensor nodes with low energy. To this end, we consider energy sharing between sensor nodes. We model the problem as a mixed integer linear program (MILP). Advantageously, our MILP models non-linear energy conversion rates. We also outline a heuristic for large-scale networks. Our results show energy sharing and non-linear energy conversion rates prolong coverage lifetime. Finally, our heuristic achieves 90% of the optimal coverage lifetime.

Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.

2521 Background: AMG 228 is an agonistic human IgG1 monoclonal antibody that binds to GITR (CD357), a TNFSFR costimulatory molecule expressed by effector/regulatory T cells. Dose escalation of this open label, first in human, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and maximum tolerated dose (MTD) and recommended phase 2 dose of AMG 228 in pts with advanced solid tumors. Methods: Pts with refractory advanced colorectal cancer (n = 13), squamous cell carcinoma of head and neck (n = 10), non–small cell lung cancer (n = 2), urothelial transitional cell carcinoma (n = 4), and melanoma (n = 1) received AMG 228 IV Q3W. Dose escalation was in two stages: single-pt cohorts until AMG 228-related grade &gt; 2 adverse events (AEs), efficacy, or 90 mg dose reached (4 cohorts: 3, 9, 30, and 90 mg), followed by rolling six design (n = 2 to 6) until MTD or highest planned dose of 1200 mg reached (5 cohorts: 180, 360, 600, 900, and 1200 mg). Primary endpoints included incidence of dose-limiting toxicities (DLTs) and AEs and PK. Additional endpoints were objective response (RECIST 1.1) and evidence of biological activity. Results: In total, 30 pts (median age 63 y) were treated (3, 9, 30, and 90 mg, n = 1; 180 mg, n = 6; 360 mg, n = 4; 600 mg, n = 6; 900 mg, n = 4; 1200 mg, n = 6). Twenty-seven (90%) pts had treatment-emergent AEs; the most common were hypophosphatemia (23%), fatigue (23%), anemia (23%), nausea (20%), and pyrexia (20%). No DLTs occurred; the MTD was not reached. AMG 228 exposure was dose-related, with PK profiles at low doses (3 to 90 mg) consistent with target mediated drug disposition; doses &gt; 360 mg achieved serum levels needed for 95% receptor occupancy on activated PBMCs. No evidence of T cell activation was observed despite complete target coverage in both tumor and peripheral blood. Among 29 evaluable pts, none had an objective response. Conclusions: In this population of pts with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200 mg), showing favorable PK. However, no clinical or immunological activity was observed in this limited number of pts. Clinical trial information: NCT02437916.

On Complete Target Coverage in Wireless Sensor Networks With Random Recharging Rates

A fundamental problem in Wireless Sensor Networks (WSNs) is determining the minimum active time of a set of sensor nodes such that they monitor all targets for the maximum time. However, existing solutions do not consider random recharging rates and staled battery level information, resulting in an activation schedule that is not realizable by sensor nodes. Henceforth, we propose a Stochastic Programming (SP) based approach that considers random battery levels. Experimental results show our SP approach achieves 80% of the theoretically achievable coverage lifetime.

A Novel Approach to Postmastectomy Radiation Therapy Using Scanned Proton Beams

Postmastectomy radiation therapy (PMRT), currently offered at Massachusetts General Hospital, uses proton pencil beam scanning (PBS) with intensity modulation, achieving complete target coverage of the chest wall and all nodal regions and reduced dose to the cardiac structures. This work presents the current methodology for such treatment and the ongoing effort for its improvements. A single PBS field is optimized to ensure appropriate target coverage and heart/lung sparing, using an in-house-developed proton planning system with the capability of multicriteria optimization. The dose to the chest wall skin is controlled as a separate objective in the optimization. Surface imaging is used for setup because it is a suitable surrogate for superficial target volumes. In order to minimize the effect of beam range uncertainties, the relative proton stopping power ratio of the material in breast implants was determined through separate measurements. Phantom measurements were also made to validate the accuracy of skin dose calculation in the treatment planning system. Additionally, the treatment planning robustness was evaluated relative to setup perturbations and patient breathing motion. PBS PMRT planning resulted in appropriate target coverage and organ sparing, comparable to treatments by passive scattering (PS) beams but much improved in nodal coverage and cardiac sparing compared to conventional treatments by photon/electron beams. The overall treatment time was much shorter than PS and also shorter than conventional photon/electron treatment. The accuracy of the skin dose calculation by the planning system was within ±2%. The treatment was shown to be adequately robust relative to both setup uncertainties and patient breathing motion, resulting in clinically satisfying dose distributions. More than 25 PMRT patients have been successfully treated at Massachusetts General Hospital by using single-PBS fields. The methodology and robustness of both the setup and the treatment have been discussed.

Multi-layer Genetic Algorithm for Maximum Disjoint Reliable Set Covers Problem in Wireless Sensor Networks

Densely deployment of sensors is generally employed in wireless sensor networks to ensure complete target coverage for a long period of time. Many sensors scheduling techniques have been recently proposed for prolonging the network lifetime. Scheduling sensors into a maximum number of disjoint sets has been modeled, in the literature, as disjoint set covers (DSC) problem which is a well-known NP-hard optimization problem. Unlike other attempts which considers only a simple disk sensing model, this paper addresses the problem of finding the maximum number of set covers while considering a more realistic sensing model to handle uncertainty into the sensors' target-coverage reliability. The paper investigates the development of a simple multi-layer genetic algorithm (GA) whose main ingredient is to support selection of a minimum number of sensors to be assigned to maximum number of set covers. With the aid of the remaining unassigned sensors, the reliability of DSCs provided by the GA, can further be enhanced by a post-heuristic step. By identifying the upper bound of number of disjoint set covers, the GA can successively construct covers, each of which is of minimal sensor cost. Performance evaluations on solution quality in terms of both number of set covers and coverage reliability are measured and compared through extensive simulations, showing the effectiveness of the proposed GA.

Novel Algorithms for Complete Targets Coverage in Energy Harvesting Wireless Sensor Networks

This paper addresses the problem of maximizing the network lifetime of rechargeable Wireless Sensor Networks (WSNs) whilst ensuring all targets are monitored continuously by at least one sensor node. The objective is to determine a group of sensor nodes, and their wake-up schedule such that within a time interval, one subset of nodes are active whilst others enter the sleep state to conserve energy as well as recharge their battery. We propose a Linear Programming (LP) based solution to determine the activation schedule of sensor nodes whilst affording them recharging opportunities and at the same time ensures complete target coverage. The results show our LP solution achieves more than twice the performance in terms of network lifetime as compared to similar algorithms developed for finite battery WSNs. However, it is computationally expensive. We therefore propose Maximum Utility Algorithm (MUA), a few orders of magnitude faster approach that achieves 3/4 of the network lifetime obtained by our LP solution.

Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

To determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment. A total of 10 WG implants were used to generate 10 WG and 20 HG (left and right) treatment plans optimized with the inverse planning simulation annealing algorithm using Oncentra MasterPlan (Nucletron B.V., Veenendaal, The Netherlands). The standard distribution of 17-18 catheters designed for WG was used to generate HG plans. The same OARs namely bladder, rectum, and urethra contours and dose constraints were applied for HG and WG plans. The HG contour was a modification of the WG contour whereby the urethra divided the prostate into HGs. The prescription dose was 7.25 Gy×6. Evaluated dose parameters were target dose D90, V100, and V150 and D0.1 cc, D1 cc, and D2 cc to OARs. The HG plans had a D90, V100, and V150 to the HG target of 112%, 97.6%, and 33.8%, respectively. The WG plans had a D90, V100, and V150 to the WG target of 108%, 98.8%, and 26.5%, respectively. The OAR D2 cc doses were significantly lower in HG vs. WG plans: rectum (53.1% vs.64.1%, p<0.0001), bladder (55.9% vs. 67.5%, p<0.0001), and urethra (69.3% vs. 95.2%, p<0.0001). In the present model, HG plans yielded a statistically significant decreased radiation dose to OARs and provided complete target coverage with a catheter array designed for WG coverage. The good dosimetry results obtained in this study support the feasibility of HG brachytherapy by using a subset of the WG catheter array. Catheter distribution and dosimetry refinements tailored to subtotal prostate brachytherapy should be explored to see if further improvements in dosimetry can be achieved.

High-Dose-Rate Prostate Brachytherapy Consistently Results in High Quality Dosimetry

We performed a dosimetry analysis to determine how well the goals for clinical target volume coverage, dose homogeneity, and normal tissue dose constraints were achieved with high-dose-rate (HDR) prostate brachytherapy. Cumulative dose-volume histograms for 208 consecutively treated HDR prostate brachytherapy implants were analyzed. Planning was based on ultrasound-guided catheter insertion and postoperative CT imaging; the contoured clinical target volume (CTV) was the prostate, a small margin, and the proximal seminal vesicles. Dosimetric parameters analyzed for the CTV were D90, V90, V100, V150, and V200. Dose to the urethra, bladder, bladder balloon, and rectum were evaluated by the dose to 0.1 cm(3), 1 cm(3), and 2 cm(3) of each organ, expressed as a percentage of the prescribed dose. Analysis was stratified according to prostate size. The mean prostate ultrasound volume was 38.7 ± 13.4 cm(3) (range: 11.7-108.6 cm(3)). The mean CTV was 75.1 ± 20.6 cm(3) (range: 33.4-156.5 cm(3)). The mean D90 was 109.2% ± 2.6% (range: 102.3%-118.4%). Ninety-three percent of observed D90 values were between 105 and 115%. The mean V90, V100, V150, and V200 were 99.9% ± 0.05%, 99.5% ± 0.8%, 25.4% ± 4.2%, and 7.8% ± 1.4%. The mean dose to 0.1 cm(3), 1 cm(3), and 2 cm(3) for organs at risk were: Urethra: 107.3% ± 3.0%, 101.1% ± 14.6%, and 47.9% ± 34.8%; bladder wall: 79.5% ± 5.1%, 69.8% ± 4.9%, and 64.3% ± 5.0%; bladder balloon: 70.3% ± 6.8%, 59.1% ± 6.6%, and 52.3% ± 6.2%; rectum: 76.3% ± 2.5%, 70.2% ± 3.3%, and 66.3% ± 3.8%. There was no significant difference between D90 and V100 when stratified by prostate size. HDR brachytherapy allows the physician to consistently achieve complete prostate target coverage and maintain normal tissue dose constraints for organs at risk over a wide range of target volumes.

Volumetric Modulated Arc–Based Hypofractionated Stereotactic Radiotherapy for the Treatment of Selected Intracranial Arteriovenous Malformations: Dosimetric Report and Early Clinical Experience

To evaluate, with a dosimetric and clinical feasibility study, RapidArc (a volumetric modulated arc technique) for hypofractionated stereotactic radiotherapy treatment of large arteriovenous malformations (AVMs). Nine patients were subject to multimodality imaging (magnetic resonance, computed tomography, and digital subtraction angiography) to determine nidus and target volumes, as well as involved organs at risk (optical structures, inner ear, brain stem). Plans for multiple intensity-modulated arcs with a single isocenter were optimized for a fractionation of 25 Gy in 5 fractions. All plans were optimized for 6-MV photon beams. Dose-volume histograms were analyzed to assess plan quality. Delivery parameters were reported to appraise technical features of RapidArc, and pretreatment quality assurance measurements were carried out to report on quality of delivery. Average size of AVM nidus was 26.2 cm(3), and RapidArc plans provided complete target coverage with minimal overdosage (V(100%)= 100% and V(110%) < 1%) and excellent homogeneity (<6%). Organs at risk were highly spared. The D(1%) to chiasm, eyes, lenses, optic nerves, and brainstem (mean ± SD) was 6.4 ± 8.3, 1.9 ± 3.8, 2.3 ± 2.2, 0.7 ± 0.9, 4.4 ± 7.2, 12.2 ± 9.6 Gy, respectively. Conformity index (CI(95%)) was 2.2 ± 0.1. The number of monitor units per gray was 277 ± 45, total beam-on time was 2.5 ± 0.3 min. Planning vs. delivery γ pass rate was 98.3% ± 0.9%. None of the patients developed acute toxicity. With a median follow-up of 9 months, 3 patients presented with deterioration of symptoms and were found to have postradiation changes but responded symptomatically to steroids. These patients continue to do well on follow-up. One patient developed headache and seizures, which was attributed to intracranial bleed, confirmed on imaging. Hypofractionated stereotactic radiotherapy can be successfully delivered using the RapidArc form of volumetric arc technology for intracranial AVMs. The quality of delivery and calculated parameters are in agreement with each other and are in line with published reports for other sites.